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Abstract Chronic pressure-overload and diabetes melli-
tus are two frequent disorders affecting the heart. We
aimed to characterize myocardial structural and functional
changes induced by both conditions. Pressure-overload was
established in Wistar-han male rats by supra-renal aortic
banding. Six-weeks later, diabetes was induced by strep-
tozotocin (65 mg/kg,ip), resulting in four groups: SHAM,
banding (BA), diabetic (DM) and diabetic-banding (DB).
Six-weeks later, pressure–volume loops were obtained and
left ventricular samples were collected to evaluate altera-
tions in insulin signalling pathways, extracellular matrix as
well as myofilament function and phosphorylation. Pres-
sure-overload increased cardiomyocyte diameter (BA
22.0 ± 0.4 lm, SHAM 18.2 ± 0.3 lm) and myofilament
maximal force (BA 25.7 ± 3.6 kN/m2, SHAM 18.6 ±
1.4 kN/m2), Ca2? sensitivity (BA 5.56 ± 0.02, SHAM
5.50 ± 0.02) as well as MyBP-C, Akt and Erk phosphor-
ylation, while decreasing rate of force redevelopment (Ktr;
BA 14.9 ± 1.1 s-1, SHAM 25.2 ± 1.5 s-1). At the
extracellular matrix level, fibrosis (BA 10.8 ± 0.9%,
SHAM 5.3 ± 0.6%), pro-MMP-2 and MMP-9 activities
increased and, in vivo, relaxation was impaired (s; BA
14.0 ± 0.9 ms, SHAM 12.9 ± 0.4 ms). Diabetes increased
cardiomyocyte diameter, fibrosis (DM 21.4 ± 0.4 lm,
13.9 ± 1.8%, DB 20.6 ± 0.4 lm, 13.8 ± 0.8%, respec-
tively), myofilament Ca2?sensitivity (DM 5.57 ± 0.02, DB
5.57 ± 0.01), advanced glycation end-product deposition
(DM 4.9 ± 0.6 score/mm2, DB 5.1 ± 0.4 score/mm2,
SHAM 2.1 ± 0.3 score/mm2), and apoptosis, while
decreasing Ktr (DM 13.5 ± 1.9 s
-1, DB 15.2 ± 1.4 s-1),
Akt phosphorylation and MMP-9/TIMP-1 and MMP-1/
TIMP-1 ratios. Diabetic hearts were stiffer (higher end-
diastolic-pressure: DM 7.0 ± 1.2 mmHg, DB 6.7 ± 0.7
mmHg, SHAM 5.3 ± 0.4 mmHg, steeper end-diastolic-
pressure–volume relation: DM 0.59 ± 0.18, DB 0.83 ±
0.17, SHAM 0.41 ± 0.10), and hypo-contractile
(decreased end-systolic-pressure-volume-relation). DB
animals presented further pulmonary congestion (Lungs/
body-weight: DB 5.23 ± 0.21 g/kg, SHAM 3.80 ± 0.14
g/kg) as this group combined overload-induced relaxation
abnormalities and diabetes-induced stiffness. Diabetes
mellitus and pressure overload led to distinct diastolic
dysfunction phenotypes: while diabetes promoted myo-
cardial stiffening, pressure overload impaired relaxation.
The association of these damages accelerates the progres-
sion of diastolic heart failure progression in diabetic-
banded animals.
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Introduction
Diastolic left ventricular (LV) dysfunction importantly
contributes to heart failure (HF) with normal ejection
fraction (EF) [17]. Diastolic dysfunction is usually ascribed
to impaired relaxation or abnormal myocardial passive
properties [23, 52]. This condition, which has a poor
prognosis, represents nearly half of the hospitalizations for
HF and a growing problem in industrialized nations [52].
Experimental and clinical evidences show that diabetes
mellitus is associated with abnormalities of systolic and
diastolic performance [52]. The streptozotocin (STZ)-
induced diabetic rat, a hypoinsulinemic model of type 1
diabetes, has been used to define the pathophysiology of
hyperglycaemic conditions [25, 41], showing significant
changes in cardiomyocytes and myocardial mechanical
properties such as prolongation of contraction and relaxa-
tion [5, 32]. Functionally, this altered kinetic has been
mostly attributed to impaired intracellular Ca2? homeo-
stasis [9]. Additionally, changes in the intrinsic passive
properties of the heart, such as advanced glycation end-
products (AGE) [3] and collagen [44] deposition induce
extracellular matrix (ECM) abnormalities hence, contrib-
uting to increased stiffness and impaired ventricular filling
[52]. Furthermore, matrix metalloproteinases (MMP) and
their tissue-specific inhibitors (TIMP) regulate a complex
balance between collagen degradation and its deposition,
therefore contributing to matrix remodelling in several
cardiac diseases [28] such as in diabetic cardiomyopathy.
AGE receptors, RAGE, are currently being object of many
investigations due to their role in promoting inflammation
and fibrosis in hyperglycaemic conditions. Moreover, many
of the current antifibrotic therapies exert their effects via
RAGE modulation [20, 46].
Another frequent cause for HF is chronic pressure-
overload. Over 10% of the population suffers from severe
hypertension. Initially, it induces myocardial hypertrophy
as an adaptative response by which the LV compensates for
increased afterload [13]. Longstanding pressure-overload,
however, results in myocardial systolic and diastolic dys-
function, structural damages and, later on, congestive HF
[1, 7]. Despite improvements in anti-hypertensive treat-
ment, therapy-resistant hypertension often leads to cardiac
failure.
Hypertension is more prevalent among the diabetic
population and exacerbates the extent of diabetic cardio-
myopathy [10, 25, 41]. Even so, functional and structural
cardiac consequences of combined hypertension and dia-
betes are still unclear, especially those related with changes
in single cardiomyocytes, in the ECM, size of the ven-
tricular chamber and diastolic function. So far, the results
are conflicting reporting either increased [31] or decreased
myocardial stiffness [33].
Additionally, it is currently accepted that insulin exerts
its pro-hypertrophic effects on responsive tissues such as
the myocardium both in diabetic and in overloaded hearts.
These effects mediate hypertrophy by distinct mechanisms:
insulin activates Akt-1 pathway that mediates glucose
uptake. Akt-1 phosphorylates and inactivates glycogen
synthases kinase-3b (GSK-3b), a well-recognized inhibitor
of nuclear transcription governing the hypertrophic process
via the nuclear factor of activated T-cells (NFAT) [30]. In
addition, there are other insulin-mediated, but Akt-1-inde-
pendent, pathways that may be operative, most notably the
extracellular signal-regulated kinase (ERK)/mitogen-acti-
vated protein (MAP) kinase pathways [30]. Significant
cellular evidence exists for an insulin-induced activation of
the p38 MAP kinase pathway. Therefore, we explored
insulin signaling pathways underlying the functional
changes induced by diabetes and chronic pressure
overload.
The present study aimed to analyse and describe the
myocardial morphological and functional changes induced
by diabetes and/or pressure-overload from an integrative
perspective that is studying changes at the molecular,
cellular and intact heart level, particularly in terms of
insulin signalling pathways, force measurements in iso-
lated cardiomyocytes, phosphorylation status of myofila-
mentary proteins, ECM and in vivo pressure–volume
haemodynamics.
Materials and methods
Animal models
All animal experiments were performed according to the
Portuguese law for animal welfare and accordingly to the
Guide for the Care and Use of Laboratory Animals pub-
lished by the National Institutes of Health (NIH Publication
85-23, Revised 1996). The Faculty of Medicine of Porto is
a governmental institution, granted approval by the Por-
tuguese government to perform animal experiments. Male
Wistar-han rats were housed in groups of 4 animals per
cage in a controlled environment under a 12:12-h light–
dark cycle at a room temperature of 22C, with free supply
of food and water.
After an overnight fast, rats were anaesthetized with an
intraperitonial injection of ketamine:xylazine (75:5 mg/kg)
and surgical banding was performed as previously descri-
bed [28]. Six weeks after surgery, rats fasted for 5 h were
randomly injected with STZ (65 mg/kg, ip) or an equal
volume of citrate buffer (pH = 4.5). One week later, dia-
betic state was assessed by measurement of non-fasting
serum glucose concentration. This resulted in four experi-
mental groups: SHAM (n = 10), banded (BA, n = 10),
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diabetic (DM, n = 14) and diabetic-banded (DB, n = 14).
We started by inducing pressure overload as this model
provides a gradual injury that takes several weeks to
develop considerable myocardial hypertrophy and, there-
fore, progressing slower than the fast STZ-diabetic model.
This way, we chose to induce first chronic pressure over-
load and latter, diabetes mellitus. Twelve weeks after the
surgical procedure, haemodynamic evaluation with con-
ductance catheters was performed.
Haemodynamic measurements
Instrumentation
Rats were anaesthetized by inhalation with a mixture of 4%
sevoflurane with oxygen, intubated for mechanical venti-
lation (respiratory frequency 100 min-1 and weight-
adjusted tidal volume; Harvard Small Animal Ventilator-
Model 683) and placed over a heating pad (37C). The
right jugular vein was cannulated for fluid administration
(prewarmed 0.9% NaCl solution) to compensate for peri-
operative fluid losses. A median sternotomy was performed
to expose the heart and the pericardium was widely
opened. A 2F microtip pressure–volume conductance
catheter (SPR-838, Millar Instruments) was inserted by an
apical puncture into the LV cavity along its long axis. The
catheter was connected to MVP-300 conductance system
(Millar Instruments), coupled to PowerLab16/30 converter
(AD Instruments) and a personal computer for data
acquisitions. After complete instrumentation, the animal
preparation was allowed to stabilize for 15 min. Haemo-
dynamic recordings were made with respiration suspended
at the end of expiration under steady-state conditions or
during preload reductions (vena cava occlusion). Parame-
ters from conductance catheter were recorded at a sampling
rate of 1,000 Hz, in order to accurately capture all of the
features of the pressure–volume waveforms produced by
the fast-beating rat hearts. Data were stored and analyzed
with Millar conductance data acquisition and analysis
software (PVAN3.5).
Measured parameters
Heart rate, stroke volume, end-diastolic volume (LV-VED),
end-systolic volume (LV-VES), EF, end-diastolic pressure
(LV-PED) and end-systolic pressure (LV-PES) were deter-
mined from the pressure–volume tracings. Effective sys-
temic arterial elastance (Ea), as a measure of LV afterload,
was calculated dividing LV-PES by stroke volume. Maxi-
mal LV wall-stress [LV-WSTRESS] was calculated from LV
pressure [P(t)] and volume [V(t)] and LV wall volume
(Vwall) according to the following formula: LV-
WSTRESS = P(t){1 ? 3[V(t)/Vwall]} [16]. LV wall volume
(Vwall) was approximated as the sum of the LV free wall
mass and half of the interventricular septum mass. Relax-
ation rate was estimated with the time constant s using the
Glantz method.
The intrinsic myocardial function relatively load-inde-
pendent parameters LV end-systolic pressure–volume
relation (ESPVR) and end-diastolic pressure–volume rela-
tion (EDPVR) were determined from pressure–volume
loops recorded during transient occlusion of the inferior
vena cava by external compression of the vessel.
Conductance calibration
Parallel conductance values were obtained by the injection
of approximately 100 ll of 10% NaCl into the right atrium.
Calibration from relative volume units (RVU) conductance
signal to absolute volumes (ll) was undertaken using a
previously validated method of comparison to known
volumes in Perspex wells [50].
Morphometric analysis and tissue preparation
After haemodynamic data collection, the anaesthetized
animals were sacrificed through cardiectomy and exsan-
guination. The heart, lung and LV ? septum (LV ? S)
were dissected, weighed separately, normalized to body
weight (BW) and divided in two fragments: one was
immediately frozen with liquid nitrogen to preserve the
phosphorylation status, and the other stored in 10% for-
malin for histological analysis.
Quantitative histomorphometry and extracellular matrix
analysis
Histomorphological analysis of LV samples was performed
on Picrosirius red and haematoxylin-and-eosin-stained
4-lm-thick-sections of tissue placed in 10% formalin.
Section images were acquired with a microscope (950)
and analysed with Slidebook 4.0 software (3I, Denver,
Colorado) to determine cardiomyocyte diameter and
myocardial fibrosis. As previously described and validated
[43], cardiomyocyte diameter was calculated by averaging
over 15 representative cardiomyocytes per animal (SHAM
n = 5, DM n = 4, BA n = 5 and DB n = 5) after mea-
suring the diameter perpendicularly to the outer contour of
the cell at the nucleus level. Picrosirius-red staining is
widely used to evaluate myocardial fibrosis. Red staining
with Picrosirius is accompanied by a pronounced increase
in birefringence, which is an unequivocal indication of the
presence of collagen and reticulin fibres [21, 48].We de-
waxed and hydrated paraffin sections, stained 4-lm-slide
with picro-Sirius red for 1 h, followed by two washes with
acidified water. Finally, we dehydrated in 80, 90 and three
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changes of 100% ethanol, cleared in xylene and mounted in
a resinous medium. We examined the sections on a
polarized microscope (9400) always using similar light
intensity and photographed the slides using a digital cam-
era. Slidebook software was used to calculate the sum of all
connective tissue areas divided by the sum of connective
tissue and muscle areas averaged over 4–6 representative
fields of the section. Areas of reparative and perivascular
fibrosis were excluded. The intensity of the red colour can
be measured by microdensitometry to provide estimates of
collagen content in different parts of a tissue.
Quantification of the AGE N-e(carboxymethyl)lysine
(CML) was performed using a specific anti-CML mono-
clonal antibody as previously described [37].
LV myocardial MMP extraction, zymography and
immunoblotting as well as TIMPs quantification was per-
formed on 6 SHAM, 6 BA, 6 DM and 6 DB rats [28].
Briefly, to detect MMP lytic activity, the myocardial
extracts were loaded onto electrophoretic gels (SDS-
PAGE) containing 1 mg/mL of gelatin or collagen (type III
denatured), under nonreducing conditions. Gels were run at
15 mA/gel through the stacking phase (4%) and at 20 mA/
gel for the separating phase (10%), at 4C in a running
buffer. The gels were stained with Coomassie blue R-250
for 30 min and destained by changing the solution for
60 min, to be subsequently dried and analyzed, looking for
zones of enzymatic activity as indicated by negative
staining. In all zymograms, prestained molecular weight
markers (Novex, San Diego, CA) and positive controls
(Oncogene, San Diego, CA) were included. The zymo-
grams were analysed by a densitometer (GS710 Densi-
tomer; Bio-Rad, Hercules, CA) and data were expressed as
optical density (OD), reported to 1 mg/mL protein content.
The TIMP-1 and TIMP-2 assays were performed by
commercial ELISA kits (Biotrak; Amersham Pharmacia
Biotech-England) that detect total TIMP-1 or TIMP-2.
TIMP concentrations were expressed as ng/ml reported to
mg/ml of proteins of each sample.
Force measurements in isolated cardiomyocytes
Force measurements were performed in single, triton-per-
meabilized cardiomyocytes mechanically isolated from LV
free wall samples as described previously [4, 43], in which
active (Factive) and passive forces (Fpassive) were measured
to detect systolic and/or diastolic dysfunction at the myo-
filament level.
In brief, biopsy samples were defrosted in relaxing
solution (free of Ca2?), mechanically disrupted and incu-
bated for 5 min in relaxing solution supplemented with
0.2% Triton X-100 to remove all membrane struc-
tures. Subsequently, cardiomyocytes were washed and
attached between a force transducer and a motor (*3
cardiomyocytes per animal for a total of 5 SHAM, 5 BA, 5
DM and 5 DB LV samples). After setting sarcomere
length (SL) at 2.2 lm, the myocytes were subjected to
both relaxing and Ca2? activating solutions. Their pCa
(-log10[Ca
2?]) ranged from 9.0 (relaxing) to 4.5 (maximal
activation) to produce a force-pCa relation. Maximal
activation at pCa 4.5 was used to calculate maximal
calcium-activated isometric force. After transferring the
cardiomyocyte from relaxing to activating solution, iso-
metric force started to develop (Ftotal). Once a steady-state
force level was reached, the cell was shortened within 1 ms
to 80% of its original length (slack test) to determine the
baseline of the force transducer. The distance between
the baseline and the steady force level is Ftotal. After 20 ms,
the cell was re-stretched and returned to the relaxing
solution, in which a second slack test of 10-s duration
was performed to determine resting or Fpassive. The slack
test at pCa = 4.5 allowed to measure the rate of force-
redevelopment (Ktr) since this manoeuvre resulted in the
complete dissociation of cross-bridges from actin, so that
the subsequent redevelopment of tension was related to the
rate of cross-bridge reattachment.
mRNA quantification
For gene expression analyses, RNA was extracted with
TriPure (Roche). RT-PCR was preformed with total RNA,
followed by real-time PCR analyses using the SYBR Green
method in a LightCycler 2.0 (Roche).
For the animal studies, results are relative to the mean
obtained for the SHAM group (set as arbitrary unit) and
normalized for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). Specific PCR primer pairs for the studied genes
were GAPDH, sarcoplasmatic reticulum Ca2?-ATPases-2a
(SERCA2a), phospholamban (PLB), tumor necrosis-factor-
a (TNF-a), transforming growth factor-b1 (TGF-b1),
myosin heavy-chain-a (MHC-a) and myosin heavy-chain-b
(MHC-b).
Myofilament protein phosphorylation
Myofilament protein phosphorylation was determined in
myocardial samples from five samples of each group using
Pro-Q Diamond Phosphoprotein Stain. To preserve the
endogenous phosphorylation status, frozen biopsies were
homogenized in 1 ml cold 10% trichloroacetic acid solu-
tion [TCA, dissolved in acetone containing 0.1% (w/v)
dithiothreitol (DTT)]. TCA-treated tissue pellets were
homogenized in sample buffer containing 15% glycerol,
62.5 mmol/l Tris (pH 6.8), 1% (w/v) SDS and 2% (w/v)
DTT (final concentration 2.5 lg dry weight/ll). Tissue
samples (25 lg dry weight/lane) were separated on gradi-
ent gels (Criterion, tris–HCl 4–15% gel, BioRad) and
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proteins stained for 1hour with Pro-Q Diamond Phospho-
protein Stain. Fixation, washing and de-staining were
performed according to manufacture’s guidelines (Molec-
ular Probes) [51]. Phosphorylation status of myofilament
proteins was expressed relative to each SYPRO-stained
protein content to correct for differences in sample loading
and expressed in arbitrary units (AU). Staining was visu-
alized using the LAS-3000 Image reader (Fuji, 460 nm/
605 nm Ex/Em) and signals were analysed with AIDA
software.
Western blot analysis
LV samples from of each group (SHAM n = 4, DM n = 5,
BA n = 4 and DB n = 5) were homogenized in sample
buffer (50 mM Tris–Hcl pH = 7,6, 10 mM NaCl, 5 mM
EDTA, 0.5% Triton-100, 0.1% PIC, 0.1% PHIC 1, 0.1%
PHIC 2, 0.1% PHIC 3, PMSF). Laemmli buffer (0.35 M
Tris–HCl, 4% SDS, 30% glycerol, 9.3% DTT, pH 6.8,
0.01% bromphenol blue) was added to all samples and
boiled at 95C for 5 min. Hundred lg of protein from each
sample was separated by SDS-PAGE (12.5% acrylamide
gel) prepared in duplicate. The gel was run at 100 V for
50 min, using a mini-vertical gel electrophoresis (Hoefer
SE 260; Hoefer Inc), hereafter transferred to as nitrocel-
lulose membrane (Nitrocellulose Membrane, 0.2 lm;
Bio-Rad) using a Trans-Blot SD Semi-Dry Transfer Cell
(Bio-Rad Laboratories) at 200 mA for 90 min. Nonspecific
binding to the membrane was blocked with 5% (w/v) BSA
(A2153; SIGMA) in TBS-Tween. Then we proceeded to an
overnight incubation, at 4C with gentle agitation with
anti-Akt (9272; cell signalling), anti-phospho-Akt (4058;
cell signalling), anti-Erk (9102; cell signalling), anti-
phospho-Erk (9101; cell signalling), anti-Bcl-2 (2876; cell
signalling) or anti-Bax (2772; cell signalling), all anti-
bodies were diluted from 1:1,000. The following mem-
branes were washed and incubated with fluorescently
labeled secondary antibodies: Goat anti-Rabbit IRDye
800cw and IRDye 680LT; LI-COR Biosciences, both
diluted to 1:15,000. The membranes were finally washed
and the signal detected using an Odyssey Infrared Imaging
System scanner at 800 and 700 nm (LI-COR Biosciences).
The intensity values of the detected bands were analysed
by background method. P-Erk and P-Akt were normalized
for the intensity of its non-phosphorylated signal and the
ratio of Bax and Bcl-2 intensity was calculated.
Statistical analysis
Values are presented as mean ± standard error of mean
(SEM). Differences between groups were analysed using
two-way ANOVA. When significant differences were
detected, the Student–Newman–Keuls test was selected to
perform pairwise multiple comparisons. p \ 0.05 was
accepted as significant. Mortality rates were compared with
Fisher exact test.
Results
General features
Somatic and cardiac growth of all groups is represented in
Table 1. Diabetic animals presented reduced weight gain,
and atrophic hearts when compared with euglycemic ani-
mals, despite comparable LV ? S/BW. Plasma glucose
was significantly and similarly elevated in the diabetic
groups. Other signs usually associated with diabetic state
like polyuria, polydipsia and polyphagia were found in
these animals (data not shown).
LV chronic pressure-overload imposed by aortic band-
ing induced hypertrophy as observed by the increased
LV ? S weight/BW, which was positively correlated with
LV-PES (r = 0.65, p \ 0.001). The association of pressure-
overload and diabetes increased lung weight/BW suggest-
ing pulmonary congestion and induced myocardial hyper-
trophy, altogether indicating a more advanced stage of
cardiac dysfunction in the DB group.
Table 1 General features of SHAM, BA, DM and DB groups
Parameter SHAM (n = 10) DM (n = 10) BA (n = 10) DB (n = 12)
BW (g) 393 ± 15 250 ± 7* 415 ± 13 284 ± 10* D
GW/TL (mg/mm) 56.6 ± 1.9 34.6 ± 1.2* 59.9 ± 1.4 40.9 ± 2.1* D
LV ? SW (g) 1.04 ± 0.02 0.72 ± 0.01 1.26 ± 0.07 1.01 ± 0.05 PO
LV ? S/BW (g/kg) 1.79 ± 0.05 1.92 ± 0.06 2.18 ± 0.09* 2.44 ± 0.08* PO
Lungs/BW (g/kg) 3.80 ± 0.14 4.7 ± 0.15* 3.95 ± 0.10 5.23 ± 0.21* D, INT
Plasma glucose (mg/dl) 177 ± 14 443 ± 7* 175 ± 18 427 ± 13* D
BW body weight, GW/TL gastrocnemius muscle weight/tibial length, LV ? SW left ventricle plus septum weight
Data are mean ± SEM. p \ 0.05: *versus SHAM, versus DM and versus BA. For the two-way ANOVA: p \ 0.05—the result are significant
altered by: D diabetes, PO pressure-overload, INT interaction
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Mortality rate was null in SHAM and BA, 29% in DM
(n = 4) and 14% in DB (n = 2).
Quantitative histomorphometry and extracellular
matrix analysis
At the end of the protocol, cardiomyocyte diameter was
significantly higher in DM, BA and DB than in the SHAM
group (SHAM 18.2 ± 0.3 lm, DM 21.4 ± 0.4 lm, BA
22.0 ± 0.4 lm, DB 20.6 ± 0.4 lm). Both chronic pres-
sure-overload and diabetes mellitus significantly increased
cardiomyocyte diameter, while the concomitant presence
of the two conditions (DB) did not further enlarged this
parameter as confirmed by the significant interaction
(p \ 0.001).
With regard to the ECM, BA animals presented with
higher interstitial myocardial fibrosis than SHAM. Dia-
betes promoted AGE vascular deposition and induced
even more fibrosis, together with a slight increase of
TGF-b1 expression, an effect that was similar in DM and
DB groups (Table 2). Interestingly, fibrosis significantly
correlated with AGE deposition (r = 0.55, p = 0.02)
and both AGE and fibrosis were positively correlated
with lung weight/BW (Fibrosis: r = 0.52, p = 0.03;
AGE: r = 0.50, p = 0.004) and negatively correlated
with BW (Fibrosis: r = -0.56, p = 0.01; AGE: r =
-0.53, p = 0.002).
We chose to evaluate some of the most relevant MMP
contributing to myocardial remodelling [39]. ECM changes
were evaluated in terms of collagenases (MMP-1), gela-
tinase-A (MMP-2) and gelatinase-B (MMP-9) activities.
BA group displayed higher pro-MMP-2 and MMP-9
activity than SHAM group. In contrast, DM group showed
higher TIMP-1 concentrations and lower MMP-9/TIMP-1
and MMP-1/TIMP-1 ratios, while DB exhibited reduced
MMP-1 activity when compared with SHAM animals
(Table 2).
Force measurements in isolated cardiomyocytes
Chronic pressure-overload significantly increased maximal
Factive independently of concomitant presence of diabetes
(Fig. 1a). Despite the trend towards higher Fpassive in dia-
betic groups, these values were similar between groups
when measured at various sarcomere lengths ranging from
1.6 to 2.2 lm (passive length-tension relations, data not
shown) and even after setting sarcomere length at 2.2 lm
(Fig. 1b). Myofilament Ca2?-sensitivity was significantly
increased in BA, DM and DB groups when compared with
SHAM (Fig. 1c). The Ktr was significantly decreased
in all the intervention groups (Fig. 1d). Interestingly, as
observed in Fig. 1 e, f, Factive correlated positively with
LV-PES (r = 0.51, p = 0.03) and LV ? S/BW (r = 0.47,
p = 0.04).
Molecular changes
Left ventricular expression of MHC-a was significantly
decreased in diabetic hearts (DM 0.46 ± 0.17 AU,
p = 0.003 and DB 0.34 ± 0.16 AU, p = 0.003 vs. SHAM
1.00 ± 0.21 AU and BA 0.95 ± 0.16 AU). Contrarily,
MHC-b was increased in BA group (BA 4.73 ± 1.19 AU
Table 2 Extracellular matrix changes: fibrosis, advanced glycation end-product deposition (AGE), metalloproteinase (MMP) activity and
tissue-specific matrix metalloproteinase inhibitor assessment (TIMP) in SHAM, BA, DM and DB LV samples
SHAM DM BA DB
Interstitial fibrosis (%) 5.3 ± 0.6 13.9 ± 1.8* 10.8 ± 0.9* 13.8 ± 0.8* D, PO, INT
AGE (score/mm2) 2.1 ± 0.3 4.9 ± 0.6* 2.0 ± 0.4 5.1 ± 0.4* D
TGF-b1/GAPDH mRNA (AU) 1.0 ± 0.2 1.5 ± 0.4 0.9 ± 0.2 1.6 ± 0.6
MMP-1 0.79 ± 0.26 0.74 ± 0.24 0.60 ± 0.17 0.53 ± 0.23* INT
Pro-MMP-2 (OD mm2/mg ml protein) 0.11 ± 0.04 0.11 ± 0.02 0.20 ± 0.01* 0.08 ± 0.01
MMP-2 (OD mm2/mg ml protein) 0.69 ± 0.17 0.64 ± 0.21 0.65 ± 0.08 0.67 ± 0.23
MMP-9 (OD mm2/mg ml protein) 0.08 ± 0.02 0.08 ± 0.03 0.17 ± 0.03* 0.10 ± 0.03
MMP-1/TIMP-1 (OD mm2/ng/ml) 1.60 ± 0.20 0.54 ± 0.22* 1.05 ± 0.31 0.79 ± 0.32 D
MMP-9/TIMP-1 (OD mm2/ng/ml) 0.18 ± 0.02 0.07 ± 0.02* 0.24 ± 0.05 0.14 ± 0.05 D
TIMP-1 (ng/ml mg protein) 0.50 ± 0.15 1.10 ± 0.53* 0.44 ± 0.18 0.46 ± 0.28
TIMP-2 (ng/ml mg protein) 5.99 ± 0.88 7.05 ± 1.64 6.48 ± 0.78 7.18 ± 2.56
AGE advanced glycation end-products, TGF-b1 transforming growth factor-b1, MMP-1 collagenase, MMP-2 gelatinase-A, MMP-9 gelatinase-B,
TIMP tissue-specific MMP inhibitors
Units of MMPs: OD mm2/mg ml protein. Data are mean ± SEM
p \ 0.05: *versus SHAM, versus DM and versus BA. For the two-way ANOVA: p \ 0.05—the results are significantly altered by D diabetes,
PO pressure-overload, INT interaction
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vs. SHAM 1.00 ± 0.15 AU) and further more in the dia-
betic groups (DM 7.04 ± 1.15 AU, p = 0.002 and DB
9.26 ± 1.16 AU, p = 0.002). The ratio MHC-a/MHC-b
was, therefore, significantly decreased in overloaded hearts
and even more in diabetic conditions (Fig. 2a). Regarding
calcium homeostasis, the ratio SERCA2a/PLB was similar
among groups (Fig. 2b). The myofilament protein phos-
phorylation status of the different groups was analysed in
order to explain some of the observed functional differ-
ences (Fig. 2c, d, e). Pressure-overload significantly
increased myosin-binding protein C (MyBP-C) phosphor-
ylation and myosin-light-chain-2 phosphorylation (MLC-
2), while no significant differences were observed in the
phosphorylation status of other myofilament proteins such
as Troponin I (TnI, SHAM 1.88 ± 0.31, DM 1.25 ± 0.25,
BA 1.98 ± 0.29, DB 1.90 ± 0.34), Troponin T (TnT,
SHAM 2.30 ± 0.48, DM 1.99 ± 0.34, BA 2.41 ± 0.28,
DB 3.50 ± 0.85), or desmin (SHAM 0.74 ± 0.05, DM
0.77 ± 0.18, BA 0.78 ± 0.10, DB 1.21 ± 0.16). Myocar-
dial inflammation was accessed by measuring TNF-a
expression. We found that diabetes upregulates this
pro-inflammatory cytokine (SHAM 1.00 ± 0.18, DM
1.47 ± 0.30, BA 0.96 ± 0.19, DB 1.98 ± 0.58, p = 0.04
for the effect of diabetes). Furthermore, higher Bax/Bcl-2
ratio was observed, indicating augmented apoptosis in
diabetes (Fig. 3a, b, p = 0.04).
Concerning insulin-signal pathways, chronic pressure
overload increased the ratios of P-Erk/Total-Erk
(p = 0.02) and P-Akt/Total-Akt (p = 0.04), while the hy-
poinsulinemia typically associated with the STZ-model
significantly decreased P-Akt/Total-Akt (Fig. 3c, d, e, f,
p = 0.04).
In vivo pressure–volume loops analysis
Heart rate was within the published values and presented
significantly lower values in the diabetic animals (DM
327 ± 10 bpm, DB 356 ± 11 bpm vs. SHAM 386 ± 9 bpm
and BA 388 ± 13 bpm, respectively, p \ 0.001).
Aortic banding resulted in a significant increase
in afterload as observed by the augmented LV-PES,
LV-WSTRESS and arterial elastance (Ea, Fig. 4c) for both
BA and DB when compared with SHAM and DM,
respectively. Afterload independent assessment of con-
tractility by the ESPVR was significantly lower in both
diabetic groups (Fig. 4d).
Fig. 1 Force measurements in
single-skinned cardiomyocytes.
Maximal active (kN/m2, a) and
passive force (kN/m2, b),
myofilament Ca2? sensitivity
(pCa50, c), rate constant of force
redevelopment (Ktr, s
-1, d),
correlation between LV end-
systolic pressure and active
force (r = 0.51, p = 0.03,
e) and correlation between
LV ? Septum/BW and active
force (r = 0.47, p = 0.04, f) in
SHAM (n = 5), diabetic (DM,
n = 5), banded (BA, n = 5) and
diabetic-banded (DB, n = 5)
animals. Data are
mean ± SEM. p \ 0.05:
*versus SHAM, versus DM
and versus BA
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With regard to diastolic function, relaxation rate,
assessed by s, was significantly prolonged in BA and DB
when compared with the non-overloaded animals,
independently of the association with diabetes (Fig. 5a).
On the other hand, LV-PED and EDPVR were significantly
increased in the diabetic animals (Fig. 5b, c), indicating
Fig. 2 Ratio between LV
expression of myosin heavy
chain-a (MHC)-a/MHC-b
(a) and sarcoplasmatic
reticulum Ca2?-ATPase-2a/
phospholamban (SERCA2a/
PLB, b). Phosphorylation status
of myosin-binding-protein-C
(pMyBP-C, c) and myosin-
light-chain-2 (pMLC-2, d),
normalized to total amount of
MyBP-C or MLC-2,
respectively. Data are
mean ± SEM. p \ 0.05:
*versus SHAM, versus DM
and versus BA. Representative
Pro-Q Diamond-stained gels
(e) of SHAM (n = 5), diabetic
(DM, n = 5), banded (BA,
n = 5) and diabetic-banded
(DB, n = 5) groups
Fig. 3 Western blot analyses of Bax/Bcl-2 ratio (a) revealed that
diabetes increases apoptosis in both diabetic groups (DM and DB,
p = 0.04, b). Pressure overload increased the ratio of phosphorylated/
total Erk (P-Erk/Total-Erk, p = 0.02, c, d) and P-Akt/Total-Akt (p =
0.04, e, f) while diabetes decreases the latter (p = 0.04, e, f). Data are
mean ± SEM. p \ 0.05: *versus SHAM, versus DM and versus BA
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higher LV stiffness than in euglycemic animals. Interest-
ingly, the higher stiffness of the diabetic myocardium,
which was not evident at the myofilament level, became
significant in the in vivo haemodynamic setting (repre-
sentative examples in Fig. 6). Noteworthy Ea was posi-
tively correlated with LV-PES (r = 0.75, p \ 0.001) and
that both correlated with hypertrophy (LV ? S/BW,
r = 0.51, p \ 0.01 and r = 0.69, p \ 0.001, respectively).
The relaxation time constant s correlated with LV hyper-
trophy (LV ? S/BW; r = 0.32, p = 0.03) while EDPVR
correlated with fibrosis (r = 0.69, p = 0.03) and AGE
deposition (r = 0.41, p = 0.04).
Discussion
Cardiac remodelling is a major determinant of heart failure
progression, independently of its aetiology. We found that
pressure-overload and diabetes mellitus result in distinct
myocardial structural changes leading predominantly to
relaxation abnormalities in the first and increased stiffness
in the latter.
The main findings reveal that banded animals presented
hypertrophied cardiomyocytes whose myofilaments
showed augmented Factive, MyBP-C and MLC-2 phos-
phorylation as well as an augmented insulin-signalling
activation. At the ECM level, the increased collagen
deposition was partially counterbalanced by enhanced
gelatinase (pro-MMP-2 and MMP-9) activity. In vivo,
myocardial hypertrophy was associated with relaxation
abnormalities, as observed by increased s. Diabetes pro-
moted hypertrophy and decreased Ktr. Diabetes-induced
drop in Ktr is likely to be related with MHC isoform shift.
Contrary to banded-animals, insulin-signal pathways were
less active as expected by the lower insulin levels. Besides
AGE deposition, increased TIMP-1 concentration might
have contributed to the observed increase of fibrosis,
resulting in stiffer hearts (higher LVPED and EDPVR).
Indeed, lower MMP-9/TIMP-1 and MMP-1/TIMP-1 ratios
were observed. These animals presented significant
inflammatory activation and increased myocardial apop-
tosis. The association of diabetes and pressure-overload
induced further hypertrophy, prolonged relaxation and
increased myocardial stiffness, therefore resulting in more
Fig. 4 In vivo haemodynamic measurements of systolic function.
LV end-systolic pressure (LV-PES, mmHg, a); maximal LV wall
stress (LV-WSTRESS, mmHg/ll, b); arterial elastance (Ea, mmHg/ll,
c) and end-systolic pressure–volume relation (ESPVR, mmHg/ll, d)
in SHAM (n = 10), diabetic (DM, n = 10), banded (BA, n = 10) and
diabetic-banded (DB, n = 12) animals. Data are mean ± SEM.
p \ 0.05: *versus SHAM, versus DM and versus BA
b
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severe diastolic dysfunction and worse pulmonary con-
gestion in DB animals.
Effects of chronic pressure-overload
Chronic pressure-overload can be experimentally induced
by supra-renal aortic constriction. This model displays low
mortality rate, activation of hypertrophy-inducing neuro-
humoral systems, such as the renin-angiotensin-aldoster-
one-system (RAAS), and substantial LV mass increase
when compared with similar models such as transverse
aortic constriction [49].
As expected, chronic pressure-overload increased LV-
PES, arterial elastance and LV-WSTRESS with concomitant
hypertrophy. Persistent elevation of LV-PES even after
hypertrophy indicates that the hypertrophic response was
not enough to normalize afterload at this stage. Interest-
ingly, pressure-overload significantly increased myofila-
ments’ Factive and Ca
2? sensitivity indicating that the
higher LV-PES is not only a consequence of cardiomyo-
cytes’ enlargement, but also of changes in myofilaments
intrinsic properties. The positive correlation between
Factive, LV ? S/BW and LV-PES, highlights the integration
of this hypertrophy-induced remodelling at different levels
of myocardial organization: from cardiomyocytes myofil-
aments to the whole heart.
Postranslational modification of contractile proteins
represents a very relevant area within myofilament protein
research. It is well known that phosphorylation status of
myofilament proteins modulates contractility and relaxa-
tion. Currently, MyBP-C is implicated in the kinetics of
crossbridge cycling and modulation of force production
[47]. However, the exact physiological function of its
phosphorylation in healthy or in HF myocardium remains
unclear. In the present study, we found increased MyBP-C
phosphorylation in the presence of pressure-overload-
induced hypertrophy consistent with the increased myofil-
ament Factive. Hyperphosphorylation of MyBP-C may
result from an increase of PKA-induced b-adrenergic
stimulation during hypertrophy progression [12]. Accord-
ingly, transgenic mice lacking the MyBP-C phosphoryla-
tion sites displayed depressed cardiac contractility [35]. In
addition, several studies suggest a direct relationship
between the percentage of phosphorylated MyBP-C and
cardiomyocytes’ maximal force [26]. MLC-2 was also
found to be increased in the overloaded groups. Upon
phosphorylation, this regulatory protein is able to modulate
myosin–actin interaction via actin-activated ATPase
activity, increasing the force developed by the myofila-
ments at submaximal Ca2? concentration, which indicates
an augmented Ca2? sensitivity as herein demonstrated [40].
Increased MLC-2 phosphorylation has been described in
hypertrophied hearts as a compensatory response to
enhance contractile performance and efficiency [19]. These
results are in agreement with the increased contractility and
myofilament Factive that we found in BA and DB animals
and further support our integrative hypertrophic response.
Regarding diastolic abnormalities, prolonged relaxation
observed in banded animals was positively correlated with
increased LV-PES and hypertrophy, consistent with
Fig. 5 In vivo haemodynamic measurements of diastolic function.
Time constant s (ms, a), end-diastolic pressure (LV-PED, mmHg, b)
and end-diastolic pressure–volume relation (EDPVR, mmHg/ll, c) in
SHAM (n = 10), diabetic (DM, n = 10), banded (BA, n = 10) and
diabetic-banded (DB, n = 12) animals. Data are mean ± SEM.
p \ 0.05: *versus SHAM, versus DM and versus BA
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previous studies indicating that severe or late-systolic
loading is accompanied by premature LV pressure fall and
slower relaxation [23]. Furthermore, pressure-overload
induced an increase in pro-MMP-2 and MMP-9, without
being counterbalanced by an increase of TIMP tissue con-
centration. In fact, in a compensated stage of hypertrophy,
this increase results from alterations in the myocardial
environment in response to the hypertrophic stimulus, such
as mechanical stress, neurohumoral activation and release
of inflammatory mediators [42]. Particularly, transgenic
mice lacking MMP-9 and MMP-2 have shown the ability to
prevent cardiac rupture, and decreased cardiac dilatation
and dysfunction after acute myocardial infarction [15, 18],
revealing the important role of gelatinases in the remodel-
ling process associated with cardiac hypertrophy.
The insulin-signal transduction pathway regulates sev-
eral aspects of cellular physiology, including most notably
the regulation of cellular growth and of glucose uptake and
utilization [8]. When insulin binds to insulin receptor it
activates a complex signal transduction network. The
phosphatidylinositol 3-kinase (PI3K) acting via Akt/PKB
and the MAPK/ERK are the two main pathways of that
network. PI3K is considered the main player of the
metabolic action of insulin, whereas the MAPK/Erk path-
way is mainly involved in cell growth and differentiation.
Akt phosphorylates a variety of intracellular substrates
such as glycogen synthase kinase-3 (GSK-3) and the
forkhead box O (FOXO) transcription factor family, reg-
ulating cell growth, metabolism and glucose uptake. We
found that chronic pressure overload was able to increase
insulin signalling both via Erk and via Akt pathways,
therefore supporting the idea that insulin is an important
regulator of physiological cardiac growth and muscle
metabolism. In line with our studies, previous studies
demonstrated that some pathological conditions, such as
hypertension, are linked to the chronic stimulation of PI3K/
PKB/Akt and/or MAPK pathways, which undeniably par-
ticipate in the establishment of myocardial hypertrophy [3].
Effects of diabetes mellitus
In addition to fibrosis, which has been extensively associ-
ated with diabetes [44], other post-translational modifica-
tions can alter ECM. Irreversibly formed biochemical end
products of non-enzymatic glycation, AGE, compromise
myocardial stiffness and interact with RAGE inducing
Fig. 6 a Representative
pressure–volume loops from
each experimental group during
vena cava occlusion, showing
increased LV end-systolic
pressure in both banded groups
while diabetic animals
presented increased stiffness
(LV-PED). a SHAM; b diabetic
(DM); c banded (BA) and
d diabetic-banded (DB) rats
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further fibrosis and activating a pro-inflammatory pro-
gramme. In fact, we demonstrated that vascular deposition
of AGE correlated positively with fibrosis and stiffness and
was substantially increased in DM and DB which is con-
sistent with previous reports that demonstrated that plasma
[3], arterial wall [6] and myocardial levels [2] of AGE
correlate positively with ventricular filling impairment,
indicating a role for AGE in myocardial stiffening of type-I
diabetic heart patients [3].
Regarding myofilament changes, diabetes induced a
significant drop in Ktr, which is likely to be related with
MHC isoform shift. One of the major isoform changes is
the shift from the fast MHC-a to the slow and more eco-
nomical MHC-b, representing an attempt to compensate
for the metabolic changes that take place in the diabetic
heart [14] and contributing to decreased contractility such
as the reduced ESPVR herein described.
In DM and DB animals, decreased MMP activity, par-
ticularly MMP-9/TIMP-1 and MMP-1/TIMP-1, may have
prevented collagen degradation, enhanced its deposition
and presumably contributed to increase myocardial stiff-
ness in diabetic cardiomyopathy. Indeed, Li et al. [24] had
previously shown that total collagen content correlated
negatively with the activity and expression of MMP-2 and
correlated positively with TIMP-1 expression in the myo-
cardium of diabetic rats.
Also a similar situation was shown in the most advanced
stages of other heart diseases associated with cardiac dys-
function [29]. In the present study, MMP-2 activity was,
however, similar amongst all groups, which diverges from a
previous study where reduced MMP-2 activity was
responsible for the ECM changes observed STZ-rats with
the same duration of diabetes [45]. It is currently accepted
that MMP-2 activity is inhibited by TIMP-2 and its
expression increased by TGF-b1 signalling, via Smad 7 [45]
and Smad 2/3 activation [36]. In our study we found a ten-
dency for both TIMP-2 and TGF-b1 to increase. Although
not significant, this slight increase may reconcile the dif-
ferences herein reported. Moreover, several animal models
have demonstrated a time-dependent change in MMP
expression and activity according to the extent of myocar-
dial remodelling [38]: increasing in compensated hyper-
trophy, but decreasing throughout progression to HF [27],
even when ejection fraction was still preserved [29, 42].
We should emphasize that sometimes semi-quantitative
assessment of cardiac fibrosis may not allow dissecting the
effects of pressure-overload from those associated with
diabetes. In our experiment different patterns of MMP
activities and TIMP concentrations were observed in the
two conditions, inasmuch as the fibrosis observed in banded
rats was associated with increased MMP activity, enhancing
enzymatic collagen degradation, whereas diabetes-related
ECM deposition was coupled with increased TIMP
concentration, i.e. higher inhibition of collagenolytic
activity. These data indicate that cardiac fibrosis progres-
sion during either chronic pressure-overload or experi-
mental diabetes induces different mechanisms in the ECM
turnover process. In the former condition, increased after-
load stimulates collagen deposition and enhanced MMP
lytic activity, whereas in the latter metabolic changes are
associated with increased TIMP concentrations, which
inhibit ECM degradation, promoting further fibrosis. The
present experiment indicates that these qualitative differ-
ences in collagen deposition are associated with a different
pattern of ECM turnover, as it can be gauged from the
assessment of myocardial MMP activity and TIMP
concentration.
Last, diabetic, but not the overloaded animals presented
signs of myocardial inflammation as indicated by the
observed upregulation of TNF-a, which is in line with
previous finding [22]. Volz et al. showed that sustained
pro-inflammatory signalling in the adult heart from trans-
genic mice overexpressing myocardial TNF-a is associated
with a pro-fibrotic phenotype that arises, at least in part,
from TGF-b1-mediated signalling, leading to increased
myocardial fibrosis and increased LV diastolic chamber
stiffness. Indeed, recently, high mobility group box 1
(HMGB1) has been identified as a potent innate ‘‘danger
signal’’ for the initiation of host defence or tissue repair.
By interacting with RAGE and activating NF-jB, this
factor mediates pro-inflammatory effects [46]. It was also
described that sustained activation of NF-jB under marked
hyperglycaemic conditions regulates the expression of
effectors such as TNF-a, IL-6 and TGF-b1. Although we
did not specifically evaluate HMGB1 levels we have rea-
sonable evidence (increased expression of TNF-a and
TGF-b1) to suggest that this pathway is probably involved
in myocardial injury observed in the diabetic groups.
Regarding insulin-signal transduction pathway, we
found that diabetes decreased Akt/PKB signalling, which is
consonant with the hypoinsulinaemic environment that
characterizes STZ-rats. STZ-induced diabetes has been
associated with myocardial atrophy [30], associated with
loss of contractile proteins, myocyte apoptosis and
increased interstitial fibrosis, as herein reported, and con-
sistent with the absence of the mitogenic and prosurvival
effects of insulin [30].
Effects of concomitant chronic pressure-overload
and diabetes mellitus
Concomitant pressure overload and diabetes gather relax-
ation abnormalities and stiffer hearts. Altogether, this
resulted in further LV hypertrophy and lung congestion,
decreased phosphorylation of Akt, leading to a worse
general diastolic dysfunction condition. Previous studies on
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the effects of hypertension and diabetes on intrinsic myo-
cardial function showed that they were additive, with the
greatest abnormalities resulting from the combination of
these two interventions [11, 34]. Diabetic banded animals,
which represent a worse state of decompensate hypertro-
phy, hold a more severe diastolic dysfunction as they
present both overload-induced impaired relaxation and
diabetes-induced increased chamber stiffness.
We conclude that diabetes mellitus and chronic pressure
overload led to distinct phenotypes: while overloaded
animals presented with relaxation abnormalities, the dia-
betics developed not only impaired relaxation but also, and
presumably more importantly, stiffer ventricles. Associa-
tion of overload and diabetes combines these damages in a
way that precipitates a faster progression to diastolic dys-
function and heart failure.
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